Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Fiscal Q3 Revenues Increase 3 Percent

NEW YORK – 23andMe said Thursday after the close of the market that its fiscal 2022 third quarter revenues increased nearly 3 percent to $56.9 million from $55.5 million a year earlier. The genetic testing firm attributed the gain to two months of revenue from the $400 million acquisition of telehealth platform developer Lemonaid Health in November, as well as from higher subscription revenues.

The firm's Q3 net loss more than doubled to $89.4 million, or $.21 per share, from $44.6 million, or $.46 per share, a year earlier. The firm used approximately 426.6 million weighted-average shares to calculate per-share loss in the recently completed quarter compared to about 97 million weighted-average shares a year ago. 

23andMe's R&D expenses for the three months ended Dec. 31, 2021, rose 21 percent to $50.3 million from $41.7 million a year earlier. Its SG&A costs increased 155 percent to $73.7 million from $28.9 million. 

Sunnyvale, California-based 23andMe ended the quarter with $586.2 million in cash and $1.6 million in restricted cash. 

For full-year 2022, the company is projecting revenues of $268 million to $278 million, with a net loss of $205 million to $220 million. This represents a slightly rosier forecast from earlier guidance of $250 million to $260 million in revenues and a net loss of $210 million to $225 million, thanks to the Lemonaid Health acquisition.

On a conference call Thursday, 23andMe therapeutics chief Kenneth Hillan said that the firm has now amassed a database of 12.2 million genotypes. During Q3, the company introduced new genetic risk reports for myopia and severe acne through its 23andMe+ subscription service.

On the same call, CEO Anne Wojcicki highlighted Lemonaid as a growth area. "I see us rolling out genetics-based primary care" through the Lemonaid technology platform and pharmacy, she said. 23andMe executives said they will provide more details in a forthcoming filing with the US Securities and Exchange Commission.

The company went public last June through a merger with a special purpose acquisition company. 23andMe shares were at $4.79 in the first half hour of Nasdaq trading Friday, down about 4 percent from the previous day's close. 

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.